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The outer domain (OD) of human immunodeficiency virus (HIV)-1 gp120 represents an attractive,
if difficult, target for a beneficial immune response to HIV infection. Unlike the entire gp120, the
OD is structurally stable and contains the surfaces that interact with both the primary and
secondary cellular receptors. The primary strain-specific neutralizing target, the V3 loop, lies
within the OD, as do epitopes for two cross-reactive neutralizing monoclonal antibodies (mAbs),
b12 and 2G12, and the contact sites for a number of inhibitory lectins. The OD is poorly
immunogenic, at least in the context of complete gp120, but purposeful OD immunization can
lead to a substantial antibody response. Here, we map the antibody generated following
immunization with a clade C OD. In contrast to published data for the clade B OD, the majority of
the polyclonal response to the complete clade C OD is to the V3 loop; deletion of the loop
substantially reduces immunogenicity. When the loop sequence was substituted for the epitope
for 2F5, a well-characterized human cross-neutralizing mAb, a polyclonal response to the epitope
was generated. A panel of mAbs against the clade C OD identified two mAbs that reacted
with the loop and were neutralizing for clade C but not B isolates. Other mAbs recognized both
linear and conformational epitopes in the OD. We conclude that, as for complete gp120, V3
immunodominance is a property of OD immunogens, that the responses can be neutralizing and
that it could be exploited for the presentation of other epitopes.
INTRODUCTION
In its final mature form, the envelope glycoprotein of
human immunodeficiency virus (HIV)-1 is composed of
two polypeptide chains: gp120 is responsible for binding to
the primary and secondary receptors used by the virus for
cell entry and gp41 is responsible for fusion of the viral and
host cell membranes (Fenouillet et al., 2007). An effective
neutralizing antibody response must block one of these
stages if it is to provide broad cross-protection against
infection. The initial receptor binding step, enabled by
gp120, is a predominant target for the generation of such
antibodies (Pantophlet & Burton, 2006). Antibodies to
gp120 can be broadly protective, shown by the isolation of
several monoclonal antibodies (mAbs) capable of neutral-
ization of many HIV clades both in vitro (Binley et al.,
2004) and in vivo (Baba et al., 2000; Gauduin et al., 1997;
Kitabwalla et al., 2003). While possible, however, the
absence of a functionally similar class of responses to gp120
in polyclonal serum has effectively challenged vaccine
development for HIV based on envelope alone
(Pitisuttithum et al., 2006) or in combination with other
viral antigens (Russell et al., 2007).
The basis of the failure to generate high-titre neutralizing
immune responses has been attributed to active immune
evasion mechanisms developed by HIV over time, such as
glycan shrouding of sensitive sites (Wei et al., 2003),
profuse sequence variation at key sites (Catasti et al., 1995,
1996; Zolla-Pazner et al., 1999) and structural heterogen-
eity (Moore et al., 2006; Yuan et al., 2006). As a result, each
of these areas has become a focus for immunogen design
that might elicit more beneficial immune responses than
the wild-type molecule. Recent examples include the
purposeful engineering of glycan sites to enhance immu-
nogenicity (Li et al., 2008), forced immune focus on V3
(Zolla-Pazner et al., 2008) and the generation of subunit
gp120 immunogens such as the outer domain (OD) (Chen
et al., 2007; Yang et al., 2004). The rationale for the latter
A supplementary figure and a supplementary table are available with the
online version of this paper.
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flexibility of gp120 in the immune response through
comparisons between the crystal structures of free gp120
and ligand-bound gp120 (Chen et al., 2005; Kwong et al.,
1998). These show that, of the three structurally defined
features, inner domain, bridging sheet and OD, only the
OD remains as an inflexible component following receptor
binding (Yang et al., 2004; Zhou et al., 2007). The isolated
OD is therefore a potentially invariant three-dimensional
target for vaccine design, providing that a response can be
generated which contains antibodies with appropriate
specificity (Pantophlet & Burton, 2006; Zhou et al., 2007).
Preliminary immunization with the isolated OD of HIV-1
YU2, a clade B virus, yielded a response that did not focus
on the V3 loop, wholly present within the OD, possibly as a
result of loop cleavage (Yang et al., 2004). However, a
similar immunization using the OD from HIV-1 CN54, a
clade C isolate (Rodenburg et al., 2001; Su et al., 2000),
fused to the human Fc domain resulted in a strong
response that could be mapped to the V3C3 region of
gp120 through the use of bacterially expressed gp120
fragments (Chen et al., 2007). Fc fusion appeared to target
antigen uptake to FcR-bearing antigen-presenting cells, as
immunization with an Fc fusion domain mutated in the
FcR binding site was far less immunogenic (Chen et al.,
2007). However, the fine specificity of the response was not
described, meaning it could not be determined whether V3
dominated the response (as might be expected), whether
other specificities were present, whether the serum was
neutralizing or whether substitution of the loop could be
used to redirect the response. As noted, OD is a vaccine
target primarily because of its invariant structure, but its
presentation of the V3 loop is also of interest, as several
strategies directly address the V3 loop despite its relatively
poor exposure on primary isolates (Hartley et al., 2005;
Zolla-Pazner, 2005; Zolla-Pazner et al., 2008) and the
increasing realization that V3 reactivity can be more
broadly neutralizing than once thought (Pantophlet et al.,
2007; Zolla-Pazner et al., 2008). Here, using HuFc fusion as
an immune enhancer, we compare serum responses to the
CN54 OD and parallel constructs lacking the V3 loop or
with the V3 loop replaced by the epitope for Hu-mAb 2F5
(Muster et al., 1994). The range of epitopes possible was
assessed by generation of a mAb panel to the CN54 OD,
followed by their epitope specificity and ability to
neutralize.
METHODS
Molecular biology. Escherichia coli Top10 was usedfor thepropagation
of plasmids and for cloning. Recombinant baculovirus expression used
Spodoptera frugiperda (Sf9) insect cells which were cultured in SF900-II
medium (Life Technologies) at 28 uC. A description of the cloning and
mutagenesis steps is shown in Supplementary Fig. S1, available in JGV
Online. The vectors that were used were described by Chen et al. (2007)
and Yao et al. (2004). The virus used throughout was Autographa
californica multiple nuclear polyhedrosis virus (AcMNPV) modified as
described by Zhao et al. (2003).
Recombinant baculovirus infections. Infections for virus growth
were performed at an m.o.i. of 0.01 and, for protein expression, an
m.o.i. of 3. Virus growth was typically for 6 days or until there was
considerable cytopathic effect. Sf9 cells infected for protein expression
were harvested 72 h post-infection (p.i.) and the mannosylated protein
present in the supernatant was purified as described below.
Protein purification. Sf9 cells at a density of 1–2610
6 ml
21 were
infected with the required recombinant baculoviruses; supernatants
from virus-infected cells were harvested at 3 days p.i. The
supernatants were clarified by filtration (0.45 mm )a n da p p l i e dt o
ac o l u m no fl e n t i ll e c t i nS e p h a r o s e4 B( 1 0 m lr e s i np e rl i t r e
processed supernatant, flow rate of 1 ml min
21). The column was
washed to background absorbance with 20 mM Tris/HCl pH 7.4,
0.5 M NaCl and the column was eluted using three column
volumes of 1 M methyl a-D-glucopyranoside. Positive absorption
fractions were pooled and desalted before application to a pre-
packed protein A column (Bio-Rad). The column was washed and
eluted as described by the manufacturer. Eluted proteins were
pooled and desalted into TBS and the protein concentration was
determined by a modified Bradford assay (Sigma). Where
necessary, the proteins were concentrated by spin filtration and
stored at 0.5 mg ml
21 at 280 uC.
ELISA. Microtitre plates (Thermo Labsystems) were coated overnight
with purified proteins at 10 mgm l
21 in 200 mM sodium bicarbonate.
The plates were rinsed several times with Tris-buffered saline (TBS)
containing 5% w/v dried milk powder and used immediately.
Primary antibodies, diluted in TBS containing 0.05% v/v Tween-20
(TBST), were incubated with antigen for 60 min at room temper-
ature. Unbound antibody was removed by washing five times with
TBST and the plate was incubated with HRP-conjugated anti-mouse
antibody (1:1000; Chemicon) for 1 h at room temperature. The plate
was washed extensively and incubated with 3,39,5,59-tetramethylben-
zidine dihydrochloride chromagenic substrate (Europa Bioproducts).
The reaction was stopped by addition of an equal volume of 0.5 M
HCl and the absorbance was read at 410 nm.
SDS-PAGE and Western blotting. Protein samples were separated
on pre-cast 10% Tris/HCl SDS-polyacrylamide gels (Bio-Rad) and
transferred to Immobilion-P membranes (Millipore) using a semi-dry
blotter. Filters were blocked for 1 h at room temperature using TBST
containing 5% w/v dried milk powder. Primary antibodies were used
at a dilution of 1:500 in PBS containing 0.1% Tween-20 (PBST)
containing 5% w/v dried milk powder, unless otherwise stated.
Following several washes with TBST, the membranes were incubated
for 1 h with HRP-conjugated anti-mouse antibody (Chemicon) and
the bound antibodies were detected by BM chemiluminescence
(Roche).
Immunization. Groups of three BALB/c mice were immunized
subcutaneously with 10 mg purified OD fusion protein at 2 week
intervals. No additional adjuvant was used. For polyclonal antibody
production, the individual sera from a group were pooled and the
anti-Fc reactive component was removed by incubation with an
excess of HCV E2-Fc fusion protein overnight. Antigen–antibody
complexes were removed by centrifugation and the residual serum
was assessed by Western blotting on gp120-Fc and HCV E2-Fc. If
necessary, the adsorption was repeated until reactivity was shown only
with the gp120 fusion protein. For mAb production, spleens were
harvested for fusion to myeloma cells at 60 days post-immunization.
Following fusion, cell lines were isolated by limiting dilution and their
specificity was determined by ELISA of the supernatants on the
immunogen and a non-related Fc fusion protein (HCV E2-Fc).
Positive lines were recloned and the isotypes were determined by the
mouse monoclonal antibody isotyping kit (Sigma).
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We have shown previously that the CN54 OD generates a
serum capable of V3 recognition, although the fine
specificity of the response was not described (Chen et al.,
2007). As this response was significantly different from that
described for the YU2 OD (Yang et al., 2004), we sought to
investigate the immunogenicity of the clade C OD in more
detail. To do this, we constructed two variants of the OD-
Fc molecule that were previously shown to be immuno-
genic; OD(DL3)-Fc has 29 residues from the centre of the
V3 loop sequence removed, while OD(2F5)-Fc has the
same deletion reconstructed to contain the sequence
ELDKWAS, the core epitope for the widely cross-
neutralizing human mAb 2F5 (Muster et al., 1994)
(Supplementary Fig. S1). The 2F5 epitope is part of the
wider membrane-proximal external region (MPER) pre-
sent on the HIV envelope spike and located in the
transmembrane domain, gp41. The complete MPER region
also contains the epitope for a second neutralizing mAb
4E10 and has been shown to be immunogenic in infected
individuals (Alam et al., 2008). In addition, both the OD
and its variants contained the substitutions at residues 295
and 394 that reintroduced the 2G12 epitope into the CN54
sequence that was used (Chen et al., 2007). Binding of
2G12 thus provides a sensitive measure of OD conforma-
tion before and after manipulation.
Following expression using high-throughput baculovirus
formation (Zhao et al., 2003), recombinant proteins were
purified from the supernatent of infected insect cells by
two-stage affinity purification. The eluted proteins were
characterized by reducing SDS-PAGE and Western blot-
ting; they were essentially pure, of the anticipated
molecular mass and showed little evidence of breakdown
(Fig. 1a). In particular, significant cleavage of the V3 loop
was not apparent in the parental molecule, in contrast to
that described for the HIV YU2 OD (Yang et al., 2004).
When the purified proteins were used as antigens in ELISA,
each OD-Fc fusion protein reacted equivalently with mAb
2G12, although the level of OD(DL3) was marginally
reduced when compared with the other two (Fig. 1b). As
expected, only OD(2F5)-Fc reacted with human mAb 2F5
(Fig. 1c). As before (Chen et al., 2007), b12 binding to each
OD construct was found to be negligible (data not shown).
Purified proteins were used to immunize BALB/c mice
(n53) in a standard immunization regimen using 10 mg
protein at 2 weekly intervals for 6 weeks. The sera from
each group (two per construct) were pooled and reactivity
with non-tagged CN54 gp120 was tested by ELISA. While
all the OD constructs were immunogenic in the Fc fusion
format, overall reactivity was severely reduced in the sera
generated using OD(DL3)-Fc and OD(2F5)-Fc when
compared with the parental OD-Fc molecule (Fig. 2a).
Although it was lower in titre, the response to the two
deleted molecules of the V3 loop was further analysed
using Western blotting with these sera on a variety of
antigens, including the homologous immunogens
OD(DL3)-Fc or OD(2F5)-Fc, a non-Fc but His-tagged
OD (OD-His), deglycosylated OD-His and an unrelated
fusion protein consisting of the Yersinia pestis capsular
protein caf1 fused to the 2F5 epitope (R-947). The pooled
serum response to the loop-deleted variant OD(DL3)-Fc
showed equivalent reactivity with OD(DL3)-Fc, OD(2F5)-
Fc and glycosylated OD-His, but improved reactivity to the
Fig. 1. Purification, conformation and antige-
nicity of the CN54 OD. (a) SDS-PAGE
analysis of the various OD-Fc constructs after
expression in Sf9 cells by recombinant bacu-
loviruses and purification based on Fc affinity
chromatography. Lanes: 1, OD-Fc; 2,
OD(DL3)-Fc; 3, OD(2F5); M, protein markers
(kDa). The slight molecular mass changes
associated with each construct can be seen.
(b) Reactivity of purified OD-Fc (e), OD(DL3)-
Fc (h) and OD(2F5)-Fc (g) proteins with
2G12, the epitope for which was re-engi-
neered into all variants to allow a test of
conformation. (c) Reactivity of each purified
OD-Fc protein (as in b) with 2F5.
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with R-947 (Fig. 2b). The pooled serum to OD(2F5)-Fc
showed preferential binding to the cognate antigen when
compared with the OD(DL3)-Fc serum (Fig. 2a, b,
compare lanes 1 and 2), similar preferential binding to
deglycosylated OD-His when compared with the glycosy-
lated form (compare lanes 3 and 4) and distinct reactivity
to R-947 (Fig. 2c, lane 5). From these data, we conclude
that the OD is immunogenic but that much of the
immunogenicity resides in the V3 loop. Despite a lower
titre response, the loopless OD variants retain a level of
immunogenicity which includes a response to grafted
epitopes such as the 2F5 epitope used here. In keeping with
the observation of glycan shielding (Wei et al., 2003), we
observed marginal but consistent increases (about 25%
based on densitometry) in signal when deglycosylated OD
was used as an antigen.
To provide finer specificity for the overall serum responses
to the OD and OD(DL3) immunogens, further ELISAs
were performed using a set of 20-residue biotinylated
peptides overlapping by 12 residues and spanning the
CN54 gp120 sequence. The data for each pooled serum
were compared with the serum response to the complete
CN54 gp120 generated previously using a gp120-Fc fusion
protein (Chen et al., 2007). The profile for the gp120 serum
was broadly consistent with that expected, namely an
abundant reaction to the inner domain, the V1/2 loop, the
V3 loop and the C-terminal region. When compared with
the full-length molecule, the serum to OD showed similar
V3 dominance, albeit with a shifted specificity towards the
C-terminal half of the loop (peptide D1) and an enhanced
V4 response (peptides D11 and D12), but it lacked
significant reactivity with the C terminus (peptides E7
and E8) (Fig. 3). As the N and C termini of gp120 lie close
together in the crystal structure (Kwong et al., 1998), this
might suggest that the region is presented together in the
case of gp120, a situation that cannot occur with OD as the
N terminus is absent. In addition, the shifted V3 loop
specificity and revelation of V4 indicate that, in addition to
the avoidance of the unwanted response to the inner
domain, the OD is presented differently from the complete
gp120. Despite this, when compared with the parental OD,
the pooled serum to OD(DL3) showed very poor reactivity
to any of the immobilized peptides, confirming the CN54
V3 loop as the predominant epitope within the global
serum response to the outer domain (Fig. 3).
As the OD proved to be immunogenic in the Fc format and
the fine specificity of the polyclonal response indicated the
possibility of neutralizing antibody (e.g. the V3 loop
specificity), a panel of mAbs was generated. Eight-week-old
female BALB/c mice (n53) were immunized and boosted
with OD-Fc as described before, but using a dose of 20 mg,
and the spleen cells were fused at day 60. mAbs specific for
the CN54 OD were confirmed by ELISA screening on OD-
Fc and counter-screened on an unrelated Fc fusion protein
(HCVE2-Fc) to eradicate mAbs reactive with the Fc
domain. Exhaustive screening identified eight mAbs
specific for the OD (Supplementary Table S1), of which
two mAbs (2B7 and 4E5) were identified directly as V3-
specific based on lack of reactivity with OD(DL3). The
mAbs were screened further using a variety of recombinant
gp120 fragments, competition assay and peptide binding.
From this analysis, the fine specificity of the V3 mAbs was
mapped to the centre of the loop, including the GPG
crown, for both mAbs (Fig. 4). mAb 2B7 exhibited slightly
broader binding, with strong interaction to peptide C10
upstream of the crown, while 4E5 reacted only with peptide
C11 and C12 (Fig. 4). Similarly, mAb 4D3 was unambigu-
ously mapped to a 30-residue sequence (425–455 of CN54
gp120), representing the C-terminal b-strand of the
bridging sheet (Kwong et al., 1998) (Fig. 4). The remaining
mAbs did not map unambiguously but could be distin-
guished by competition: mAb 3F8 failed to compete with
any other mAb, while mAbs 4E1, 3F9, 1G12 and 1H8 cross-
competed with each other but not with 4D3 (bridging
sheet) or 2B7/4E5 (V3 loop).
To assess neutralization, the polyclonal sera and mAbs were
used in an infectivity reduction assay in TZM-bl cells (Wei
et al., 2002), with three different HIV viruses: CN54, the
Fig. 2. Immunogenicity of OD proteins. (a) Pooled serum
response to purified OD-Fc (e), OD(DL3)-Fc (h) and OD(2F5)-
Fc (g) as measured by ELISA using CN54 gp120 as antigen.
(b, c) Western blot analysis of the sera generated to OD(DL3)-Fc
(b) and OD(2F5)-Fc (c). Lanes: 1, OD(DL3)-Fc; 2, OD(2F5)-Fc; 3,
OD-His; 4, deglycosylated OD-His; 5, R947. Protein size markers
are indicated (kDa). The blot is a composite that is typical of the
individual reactivates. The Fc-reactive portion of the serum was
removed by exhaustive absorption on an excess of a non-HIV Fc
fusion protein (HCV E2-Fc) prior to the blot.
H. Chen and others
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OD. Pepscan using overlapping peptides of the
CN54 sequence of the serum responses to OD
(b) and OD(DL3) (c) compared with that obtained
following immunization by gp120-Fc (a).
Fig. 4. Epitope mapping of mAbs, 2B7 (a), 4E5 (b) and 4D3 (c), whose binding was unambiguous on the same peptide set. (d)
Sequence details of the peptides recognized.
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derived; MN, a Tier 1 neutralization-sensitive clade B
TCLA virus; and 93MW965.26, a neutralization-sensitive
Tier 1 clade C pseudotype (Mascola et al., 2005;
Montefiori, 2004). The broadly cross-neutralizing human
mAb b12 and normal mouse sera provided positive and
negative controls, respectively. The polyclonal sera failed to
neutralize both CN54 and MN, and showed only a
marginal ability to prevent entry of the highly sensitive
93MW965.26 (not shown). The facts that the OD sera were
generally of low titre (Fig. 2) and that the gp120 serum
contained a high degree of reactivity with the inner domain
(Fig. 3) probably explains the poor levels of neutralization
seen. In contrast, the V3 loop mAbs (2B7 and 4E5)
effectively neutralized 93MW965.26 although the activity
was of limited breadth, as only marginal diminution of MN
entry was observed (Fig. 5). The neutralization ability of
2B7 was stronger than that of 4E5 (IC50 of ,2 mgm l
21 for
2B7 against 93MW965.26, compared with .10 mgm l
21 for
4E5), paralleling its broader reactivity with V3 loop
peptides (Fig. 4). 2B7 also neutralized CN54 in a dose-
dependent manner, while the activity of 4E5 was equivocal
(Fig. 5). None of the remaining mAbs demonstrated
convincing neutralization when compared with 2B7,
although 3F8 and 4E1 showed weak (~50%) neutralization
of all three viruses at 50 mgm l
21. The established cross-
clade neutralizing antibody b12 directed at the CD4
binding of gp120 site failed to neutralize CN54 and was
less effective than 2B7 with 93MW965.26 (Fig. 5).
However, it efficiently blocked entry in the MN-based
assay, in which neither 2B7 nor 4E5 clade C mAbs were
active. The data indicate that the isolated OD can elicit a
range of antibody specificities when made immunogenic
as, in this case, by fusion with Fc. Among them are V3-
loop-specific antibodies that can be powerfully neutralizing
for at least two clade C isolates.
The search for an immunogen capable of generating a
substantial cross-clade neutralizing response to HIV and
that is amenable to production and formulation as a
vaccine has been arduous (Karlsson Hedestam et al., 2008).
Moreover, the immune response to clade C viruses is
generally less well documented than that against clade B,
despite their wider distribution (Bures et al., 2002). The
relatively recent revelation that the inner domain of g120 is
flexibly mobile and effectively generates irrelevant antibody
responses has focused attention on gp120 molecules that
are ‘stabilized’ as trimers (Beddows et al., 2006, 2007; Iyer
et al., 2007; Schulke et al., 2002) or isolated fragments
(Chen et al., 2007; Yang et al., 2004). The definition of the
responses that are capable of being produced by such
fragments is therefore an important dimension of candid-
ate vaccine design. In this study, we sought to produce the
defined outer domain of a current clade C isolate in a
conformationally relevant form and we incorporated a re-
engineered epitope for the conformational human mAb
2G12 to achieve this. Neither deletion of the V3 loop nor
its substitution by the 2F5 epitope abolished 2G12
reactivity, confirming that the isolated outer domain is
conformationally immobile. Purified proteins, fused to Fc
as a molecular adjuvant, generated antibodies that reacted
both with non-tagged OD and full-length CN54 gp120.
Reactivity was largely directed to the V3 loop and, although
partially blocked by the presence of carbohydrate, the V3
loop contained a substantial proportion of reactivity with
the polypeptide backbone, not the carbohydrate, as
reactivity to deglycosylated gp120 was evident. Despite
the presence of the 2G12 epitope, no 2G12-like reactivity
was observed in any of the sera generated (data not
shown), confirming the unique properties and rarity of the
2G12 isolate (Roux et al., 2004; Trkola et al., 1996).
Although replacement of V3 with the 2F5 epitope
successfully generated a serum, its titre was low and no
Fig. 5. Neutralization of HIV isolated by mAbs. The percentage
entry into TZM-bl cells of HIV strains 93MW965.26 (a), CN54 (b)
and MN (c) was scored by luciferase activity following the addition
of 50 mgm l
”1 (filled bars), 25 mgm l
”1 (shaded bars) and 2 mg
ml
”1 (open bars) of each mAb (below the graphs).
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repeated immunization, additional adjuvants, additional
flanking sequence or multiple copies of the 2F5 sequence
could improve this. In keeping with the observed
polyclonal responses to the OD, a panel of mAbs generated
to the intact OD included V3 specificity which could be
accurately mapped and was neutralizing. As expected,
neutralization appeared to be clade-C-specific but was
potent for at least one of the V3 mAbs, 2B7, whose epitope
spanned the V3 loop crown and residues N-terminal to it, a
well-characterized immunodominant site in other HIV
isolates (Korber et al., 2007). OD would seem worthy of
further investigation for the generation of clade C
responses that omit the inner domain of gp120 or for the
presentation of alternate grafted epitopes to improve the
prospects for cross protection.
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